SCHEMBL8264012

SCHEMBL8264012

C=C/C=C(\OC)c1ccc(C)c(-c2ccc(NC(=O)c3ccncc3C)s2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IL2 P60568 5/20 0.49
▸ POLQ O75417 3/20 0.37
▸ ABL1 P00519 2/20 0.35
▸ BRAF P15056 1/20 0.33
▸ PRKACA P17612 2/20 0.32
▸ ROCK1 Q13464 2/20 0.32
▸ MAPK14 Q16539 2/20 0.32
▸ CHEK1 O14757 1/20 0.32
▸ RPS6KA5 O75582 1/20 0.32
▸ MAP4K4 O95819 1/20 0.32
▸ PRKCG P05129 1/20 0.32
▸ CDK1 P06493 1/20 0.32
▸ RPS6KB1 P23443 1/20 0.32
▸ CDK2 P24941 1/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ AKT1 P31749 1/20 0.32
▸ AKT2 P31751 1/20 0.32
▸ CLK2 P49760 1/20 0.32
▸ GSK3A P49840 1/20 0.32
▸ GSK3B P49841 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8263054 0.92 IL2 (0.42) IL2POLQBRAFMAPK14CSF1R
SCHEMBL8262105 0.87 IL2 (0.47) IL2POLQABL1BRAFMAPK14
SCHEMBL8263029 0.86 IL2 (0.44) IL2POLQABL1MAPK14LCK
SCHEMBL8264013 0.84 IL2 (0.60) IL2ABL1MAPK14MAPK13MAPK12
SCHEMBL8263042 0.82 IL2 (0.40) IL2ABL1CSF1R
SCHEMBL8259823 0.82 IL2 (0.46) IL2POLQABL1BRAF
SCHEMBL8262107 0.82 IL2 (0.45) IL2POLQABL1MAPK14LCK
SCHEMBL8262625 0.81 IL2 (0.44) IL2POLQABL1MAPK14LCK
SCHEMBL8263037 0.80 IL2 (0.46) IL2KDM4ELMNA
SCHEMBL8261524 0.80 IL2 (0.42) IL2POLQBRAFMAPK14CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006081389-A1 THIOPHENE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2006-08-03 — — WO disclosed
Send feedback